DOR 8K Grant from NIH for Ricin and Bot
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported): September
29, 2006
Commission
File No. 1-14778
DOR
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
|
DELAWARE
|
|
41-1505029
|
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification Number)
|
| |
|
|
|
1101
Brickell Ave., Suite 701 S
Miami,
FL
|
|
33131
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
| |
(305)
534-3383
|
|
| |
(Issuer’s
telephone number, including area code)
|
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
On
September 29, 2006 the Company announced that it has been awarded two additional
grants from the National Institute of Allergy and Infectious Diseases (NIAID)
totaling approximately $5.3 million to support the development of its biodefense
vaccine programs. One grant of approximately $4.8 million was awarded for the
continued development of RiVax™, a recombinant vaccine against ricin toxin. The
second grant of approximately $0.5 million has been awarded to continue
additional research on the development of BT-VACC™, a multivalent mucosal
vaccine against botulinum toxin.
Item
9.01. Financial
Statements and Exhibits.
(c)
Exhibits.
Exhibit
No. Title
99.1 Press
Release issued by the Company dated September 29, 2006.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
DOR
BIOPHARMA, INC.
By:
/s/Christopher
J. Schaber
Name:
Christopher J. Schaber
Title:
Chief Executive Officer
Date:
September 29, 2006